Insider · CIK 0001005544
Charles W Newhall III
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.). First filing Nov 20, 2023, latest Oct 10, 2025.
In brief
Charles W Newhall III files SEC Form 4 as director at SUPN (SUPERNUS PHARMACEUTICALS, INC.). Since Nov 20, 2023, Charles W Newhall III has reported 0 open-market buys worth $0 and 6 open-market sells worth $2.0M, the latest filed on Oct 10, 2025.
A track record needs three past buys with six months of prices behind them; Charles W Newhall III has 0, so none is measured yet.
The newest scored trade: sold $1.3M of SUPN on Oct 9, 2025, filed Oct 10, 2025, scored 33 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | SUPERNUS PHARMACEUTICALS, INC. | $1.3M 25,000 shares | -19% | +63% from low0% from high | |
| 21Weak | SUPERNUS PHARMACEUTICALS, INC. | $161k 3,588 shares | -3% | +51% from low0% from high | |
| 16Weak | SUPERNUS PHARMACEUTICALS, INC. | $45k 1,000 shares | -1% | +48% from low-1% from high | |
| 18Weak | SUPERNUS PHARMACEUTICALS, INC. | $64k 1,412 shares | -1% | +50% from low0% from high | |
| 31Weak | SUPERNUS PHARMACEUTICALS, INC. | $388k 10,700 shares | -8% | - | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | $70k 2,500 shares | -2% | +23% from low-34% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 25,000 0.04% of outstanding | $1.2M | Oct 9, 2025 | $270k |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 4,588 0.01% of outstanding | $206k | Aug 25, 2025 | $64k |
| Aug 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 1,412 0.00% of outstanding | $61k | Aug 22, 2025 | none |
| Nov 12, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 10,700 0.02% of outstanding | $388k | Nov 11, 2024 | none |
| Nov 16, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 2,500 0.00% of outstanding | $70k | Nov 16, 2023 | none |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +4,475 | $0.00 | $0 | 124,119 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -4,475 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +2,989 | $0.00 | $0 | 2,989 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +4,977 | $0.00 | $0 | 4,977 | Feb 20, 2026 |
| Nov 21, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +15,000 | $12.98 | $195k | 119,644 | Nov 24, 2025 |
| Nov 21, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 0 | Nov 24, 2025 |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -23,800 | $50.73 | $1.2M | 105,844 | Oct 10, 2025 |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,200 | $51.55 | $62k | 104,644 | Oct 10, 2025 |
| Aug 27, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -3,588 | $45.01 | $161k | 129,644 | Aug 29, 2025 |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,000 | $45.00 | $45k | 133,232 | Aug 27, 2025 |
| Aug 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,412 | $45.00 | $64k | 134,232 | Aug 26, 2025 |
| Nov 11, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +20,000 | $9.13 | $183k | 140,975 | Nov 12, 2024 |
| Nov 11, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -10,700 | $36.24 | $388k | 130,275 | Nov 12, 2024 |
| Nov 11, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 0 | Nov 12, 2024 |
| Nov 16, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +7,457 | $9.24 | $69k | 119,589 | Nov 20, 2023 |
| Nov 16, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -2,500 | $28.01 | $70k | 117,089 | Nov 20, 2023 |
| Nov 16, 2023 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -7,457 | $0.00 | $0 | 0 | Nov 20, 2023 |
Questions about Charles W Newhall III
Answered from the filings on this page, as of the latest one.
Is Charles W Newhall III buying or selling?
Not in the last 12 months. Charles W Newhall III's latest open-market trade on SEC Form 4 was sold $1.3M of SUPN on Oct 9, 2025.
How did Charles W Newhall III's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles W Newhall III has 0.
Where does Charles W Newhall III file Form 4?
Charles W Newhall III has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.